ROS1 and non-small cell lung carcinoma: Several EGFR-, ALK,- or ROS1-inhibitors, currently used in clinical settings, have considerably improved NSCLC patients' overall response rates (ORR), progression-free survival (PFS), and overall survival (OS), compared to standard chemotherapy.